Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1957 1
1965 2
1967 2
1968 1
1969 3
1970 3
1971 3
1972 4
1973 1
1974 3
1975 12
1976 8
1977 6
1978 5
1979 5
1980 8
1981 5
1982 9
1983 5
1984 6
1985 7
1986 4
1987 9
1988 4
1989 4
1990 7
1991 11
1992 7
1993 14
1994 11
1995 12
1996 10
1997 17
1998 12
1999 8
2000 12
2001 20
2002 16
2003 11
2004 11
2005 13
2006 14
2007 14
2008 12
2009 23
2010 20
2011 31
2012 34
2013 22
2014 21
2015 25
2016 25
2017 33
2018 29
2019 34
2020 26
2021 23
2022 16
2023 17
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

684 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Abnormality of the spleen"
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
Type 1/like CALR mutation is associated with superior survival. KARYOTYPE: Very high-risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p- and 11q-. Favorable risk abnormalities include normal karyotype or isolated +9, 13q-, 20q-, 1q abnormalities an …
Type 1/like CALR mutation is associated with superior survival. KARYOTYPE: Very high-risk abnormalities include -7, inv (3), i(17q), …
Post-splenectomy and hyposplenic states.
Di Sabatino A, Carsetti R, Corazza GR. Di Sabatino A, et al. Lancet. 2011 Jul 2;378(9785):86-97. doi: 10.1016/S0140-6736(10)61493-6. Epub 2011 Apr 5. Lancet. 2011. PMID: 21474172 Review.
The spleen is crucial in regulating immune homoeostasis through its ability to link innate and adaptive immunity and in protecting against infections. The impairment of splenic function is defined as hyposplenism, an acquired disorder caused by several haematological and i …
The spleen is crucial in regulating immune homoeostasis through its ability to link innate and adaptive immunity and in protecting ag …
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
The primary end point was a 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom response and effects on RBC transfusion requirements. Results A 35% reduction in spleen volume at week 24 was achieved by a similar proporti …
The primary end point was a 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom respons …
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen …
BACKGROUND: Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully …
Splenic irradiation for splenomegaly: A systematic review.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Zaorsky NG, et al. Cancer Treat Rev. 2017 Feb;53:47-52. doi: 10.1016/j.ctrv.2016.11.016. Epub 2016 Dec 22. Cancer Treat Rev. 2017. PMID: 28063304 Free PMC article. Review.
The most common cancers treated included chronic lymphocytic leukemia and myeloproliferative disorders; the most common regimen was 10Gy in 1Gy fractions over two weeks, and 27% of patients received retreatment. A partial or complete response (for symptoms, lab abnormalities …
The most common cancers treated included chronic lymphocytic leukemia and myeloproliferative disorders; the most common regimen was 10Gy in …
Clinical practice. Care of the asplenic patient.
Rubin LG, Schaffner W. Rubin LG, et al. N Engl J Med. 2014 Jul 24;371(4):349-56. doi: 10.1056/NEJMcp1314291. N Engl J Med. 2014. PMID: 25054718 Review. No abstract available.
The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.
Hui D, Liu L, Azami NLB, Song J, Huang Y, Xu W, Wu C, Xie D, Jiang Y, Bian Y, Sun M. Hui D, et al. Front Endocrinol (Lausanne). 2023 Jan 19;13:1107071. doi: 10.3389/fendo.2022.1107071. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743913 Free PMC article. Clinical Trial.
In this study, we aim to explore the mechanism of SLF against NAFLD, especially its effect on glucolipid metabolism, from the perspective of intestinal flora. METHODS: A prospective, randomized, controlled clinical study was designed to observe the efficacy and safe …
In this study, we aim to explore the mechanism of SLF against NAFLD, especially its effect on glucolipid metabolism, from the perspective of …
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. Harrison C, et al. N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. N Engl J Med. 2012. PMID: 22375970 Free article. Clinical Trial.
The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen volume at week 48 and at week 24, respectively, as assessed with the use of magnetic resonance imaging or computed tomography. ...At 48 we …
The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% reduction in spleen …
Normal splenic size in infants and children: sonographic measurements.
Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD. Rosenberg HK, et al. AJR Am J Roentgenol. 1991 Jul;157(1):119-21. doi: 10.2214/ajr.157.1.2048509. AJR Am J Roentgenol. 1991. PMID: 2048509
Two hundred thirty patients, from neonate to 20-year-old, had sonography because of abdominal and/or pelvic problems unrelated to the spleen. Findings on sonograms of the liver and kidneys were normal in all cases. ...The following guidelines are proposed for the upper lim …
Two hundred thirty patients, from neonate to 20-year-old, had sonography because of abdominal and/or pelvic problems unrelated to the spl …
684 results